Dynavax Technologies (DVAX) plummets over 60% in heavy volume after-hours following the stock's...

|About: Dynavax Technologies Corpor... (DVAX)|By:, SA News Editor

Dynavax Technologies (DVAX) plummets over 60% in heavy volume after-hours following the stock's release from a trading halt. Earlier, the company announced that the FDA Vaccines Advisory Committee had voted 13-1 that Heplisav data adequately demonstrated immunogenicity, but the committee also voted 8-5 with one abstention that there was insufficient data to adequately support the safety of the drug.